These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4259368)

  • 1. The significance of variations in immunoreactive and clottable fibrinogen in health and following thrombosis.
    Wolf P; Farrell GW; Walton KW
    J Clin Pathol; 1972 Jan; 25(1):36-44. PubMed ID: 4259368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of human fetal fibrinogen in umbilical cord plasma by parallel assays of immunoreactive and thrombin-clottable protein.
    Barr RD; Storbeck MM; Johnston MA; Horsewood P; Gauldie J
    Ann Clin Res; 1983 Jun; 15(3):104-8. PubMed ID: 6416136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of intravascular and extravascular coagulation on serum fibrin degradation products in rats.
    Vanstone JC; Khoury NY
    Thromb Diath Haemorrh; 1971; 25(1):142-6. PubMed ID: 4996073
    [No Abstract]   [Full Text] [Related]  

  • 4. The measurement of fibrinogen and its derivatives. II. Determination of total immunoreactive fibrinogen in the presence of soluble fibrin monomer complexes (cryoprofibrin complexes).
    Farrell GW; Wolf P
    Med Lab Technol; 1971 Jul; 28(3):319-27. PubMed ID: 4254371
    [No Abstract]   [Full Text] [Related]  

  • 5. The origin of fibrin breakdown products and the interpretation of their appearance in the circulation.
    Gallimore MJ; Tyler HM; Shaw JT
    J Clin Pathol; 1972 Mar; 25(3):185-90. PubMed ID: 4622995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysfunctional coagulation and fibrinolysis systems due to adenomyosis is a possible cause of thrombosis and menorrhagia.
    Yamanaka A; Kimura F; Yoshida T; Kita N; Takahashi K; Kushima R; Murakmai T
    Eur J Obstet Gynecol Reprod Biol; 2016 Sep; 204():99-103. PubMed ID: 27543913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clottable to immunological fibrinogen ratio in plasma from control subjects and hyperfibrinogenemic patients.
    Prisco D; Zarone N; Liotta AA; Cellai AP; Comeglio P; Fedi S; Francalanci I; Abbate R
    Haemostasis; 1995; 25(6):257-63. PubMed ID: 8586315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolysis and thrombosis of fibrinogen-modified gold nanoparticles for detection of fibrinolytic-related proteins.
    Jian JW; Chiu WC; Chang HT; Hsu PH; Huang CC
    Anal Chim Acta; 2013 Apr; 774():67-72. PubMed ID: 23567118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent plasminogen-streptokinase treatment of deep vein thrombosis.
    Scully MF; Lane DA; Sagar S; Thomas DP; Kakkar VV
    Thromb Haemost; 1977 Feb; 37(1):162-9. PubMed ID: 138963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The measurement of fibrinogen and its derivatives. 3. Thrombin clottable fibrinogen estimates in the presence of epsilon amino caproic acid, fibrinogen and fibrin degradation products.
    Farrell GW; Wolf P
    Med Lab Technol; 1971 Jul; 28(3):328-36. PubMed ID: 5314853
    [No Abstract]   [Full Text] [Related]  

  • 11. Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease.
    Lipinski B; Lipinska I; Nowak A; Gurewich V
    J Lab Clin Med; 1977 Jul; 90(1):187-94. PubMed ID: 406338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunoassay of fibrinogen and its proteolysis products.
    Catt KJ; Hirsh J; Castelan DJ; Niall HD; Tregear GW
    Thromb Diath Haemorrh; 1968 Nov; 20(1):1-6. PubMed ID: 4236937
    [No Abstract]   [Full Text] [Related]  

  • 13. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
    Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
    Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concepts of clot lysis.
    Francis CW; Marder VJ
    Annu Rev Med; 1986; 37():187-204. PubMed ID: 2939790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
    Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinogen of relatively high solubility, III. Residual clottable material in plasma deprived of the majority of fibrinogen.
    Jilg W; Hörmann H
    Hoppe Seylers Z Physiol Chem; 1974 Oct; 355(10):1316-24. PubMed ID: 4461634
    [No Abstract]   [Full Text] [Related]  

  • 17. Partial deletion of the αC-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis.
    Westbury SK; Duval C; Philippou H; Brown R; Lee KR; Murden SL; Phillips E; Reilly-Stitt C; Whalley D; Ariëns RA; Mumford AD
    Thromb Haemost; 2013 Dec; 110(6):1135-44. PubMed ID: 24048413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of deep vein thrombosis after extensive abdominal operations by the quotient between plasmin-alpha 2-antiplasmin complex and fibrinogen concentration in plasma.
    Mellbring G; Dahlgren S; Wiman B
    Surg Gynecol Obstet; 1985 Oct; 161(4):339-42. PubMed ID: 2413560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers.
    Rossi E; Mondonico P; Lombardi A; Preda L
    Thromb Res; 1988 Dec; 52(5):453-68. PubMed ID: 3146823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteolysis of fibrinogen by plasmin: the identification of thrombin-clottable fibrinogen derivatives which polymerize abnormally.
    Fletcher AP; Alkjaersig N; Fisher S; Sherry S
    J Lab Clin Med; 1966 Nov; 68(5):780-802. PubMed ID: 4224270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.